Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Isosulfan Blue · Lymphazurin, NSC-734902

Other · developed by Covidien

Approved FDA, Jul 1981
1 Registered trials

What is Isosulfan Blue?

Isosulfan blue is a synthetic visual lymphatic imaging agent injected intradermally to localize to the lymphatic system and aid in surgical identification of tumor sentinel nodes, which stain blue. It is used in the surgical management of rhabdomyosarcoma and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lymphazurin, NSC-734902, P-1888, P-4125, Vital Blue Dye (optional)
Drug type
Other
Therapy area
Oncology
Developer
Covidien
In trials of
CAH
FDA status
Approved as Lymphazurin (July 29, 1981), NDA018310
UNII
39N9K8S2A4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02509598 Phase 2 Rhabdomyosarcoma Completed CAH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaRhabdomyosarcoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.